Moxifloxacin Hydrochloride

Base Information

• Chemical Name: Moxifloxacin Hydrochloride
• CAS No.: 186826-86-8
• Molecular Formula: C21H24FN3O4.ClH
• Molecular Weight: 437.899
• Hs Code.: 2933499090
• European Community (EC) Number: 641-756-7
• UNII: C53598599T
• DSSTox Substance ID: DTXSID4045921
• Wikidata: Q27107395
• NCI Thesaurus Code: C38696
• RXCUI: 228750
• ChEMBL ID: CHEMBL1200735
• Mol file: 186826-86-8.mol

Synonyms:1-cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid;Actira;Avalox;Avelox;BAY 12 8039;BAY 12-8039;BAY 128039;BAY-12-8039;BAY-128039;BAY128039;Izilox;moxifloxacin;moxifloxacin hydrochloride;Octegra;Proflox

Chemical Property of Moxifloxacin Hydrochloride

Chemical Property:

• Appearance/Colour: 99%
• Vapor Pressure: 4.56E-17mmHg at 25°C
• Melting Point: Slightly yellow to yellow crystalline powder, mp 324-325°
• Boiling Point: 636.4 °C at 760 mmHg
• Flash Point: 338.7 °C
• PSA: 83.80000
• LogP: 3.56630
• Storage Temp.: 2-8°C
• Solubility.: H2O: soluble5mg/mL, clear (warmed)
• Water Solubility.: Sparingly soluble in water. Soluble in DMSO
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 4
• Exact Mass: 437.1517621
• Heavy Atom Count: 30
• Complexity: 727

Purity/Quality:

99% ,99.9%, ^*data from raw suppliers

Moxifloxacin Hydrochloride ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.Cl
• Isomeric SMILES: COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.Cl
• Recent ClinicalTrials: A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery
• Recent EU Clinical Trials: A Phase 3b Randomized, Double-Blind, Multi-Center Study to
• Description: Moxifloxacin is a fluoroquinolone antibiotic. It is active against 390 clinical isolates of aerobic and anaerobic Gram-positive and Gram-negative bacteria (MIC90s = ≤0.25 μg/ml), as well as clinical isolates of methicillin-susceptible and -resistant S. aureus (MIC90s = 0.12 and 2 μg/ml, respectively). Moxifloxacin is an inhibitor of E. coli DNA gyrase that is selective for DNA gyrase over E. coli topoisomerase IV (IC50s = 0.51 and 38.8 mg/L, respectively, in cell-free assays). It prevents S. aureus- or P. aeruginosa-induced increases in bronchoalveolar lavage fluid (BALF) neutrophil infiltration and reduces S. aureus- or P. aeruginosa-induced increases in lung chemokine (C-X-C motif) ligand 1 (CXCL1) and IL-1β levels in mouse models of bacterial pneumonia when administered at a dose of 100 mg/kg twice per day for two days. Moxifloxacin (100 mg/kg) decreases the number of lung and spleen colony forming units (CFUs) in a mouse model of systemic M. tuberculosis infection. Formulations containing moxifloxacin have been used in the treatment of various bacterial infections. Moxifioxacin hydrochlodde is one of the two new fluoroquinolonecarboxylic acid antibiotics introduced in 1999 for the treatment of respiratory tract infections such as community-acquired pneumonia, acute exacerbations of bronchitis or acute sinusitis. Moxifloxacin can be synthesized through a 12 step sequence from the classical 4-quinolone-3-carboxylic acid template. Some advantages of Moxifloxacin over Ciprofloxacin, another of Bayer's launched quinolones, have been shown, i.e. an enhanced activity against Gram-positive bacteria (Streptococcus pneumoniae, Clostndium pneumoniae), a favorable pharmacokinetic profile (good tissue penetration and plasma concentrations above MICs) and a lack of phototoxicity (UVA irradiation).
• Uses: Moxifloxacin Hydrochloride is an antibacterial agent that inhibits the activities of Topo II (DNA gyrase) and topoisomerase IV. acetylcholinesterase inhibitor (reversible), cognitive enhancer An antibacterial agent that inhibits the activities of Topo II (DNA gyrase) and topoisomerase IV
• Therapeutic Function: Antibacterial

Technology Process of Moxifloxacin Hydrochloride

There total 32 articles about Moxifloxacin Hydrochloride which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 96.5%

(4aS-cis)-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid-O3,O4(bis(acyloxy-O)) borate → moxifloxacin hydrochloride (186826-86-8,1246654-75-0,1346603-25-5)

Guidance literature:

With hydrogenchloride; In methanol; water; at 0 - 8 ℃; for 0.333333h; Temperature;

Reference yield: 92.9%

C27H33BFN3O8 → moxifloxacin hydrochloride (186826-86-8,1246654-75-0,1346603-25-5)

Guidance literature:

With hydrogenchloride; In methanol; at 20 ℃; for 2h; pH=3; pH-value;

Reference yield: 92.1%

moxifloxacin ethyl ester tartrate → moxifloxacin hydrochloride (186826-86-8,1246654-75-0,1346603-25-5)

Guidance literature:

With hydrogenchloride; In water; at 60 ℃; for 6h; Solvent;

upstream raw materials:

(1S,6S)-2,8-diazabicyclo[4.3.0]nonane

moxifloxacin

1-cyclopropyl-7-([S,S]-2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid monohydrochloride monohydrate

1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline-carboxylic acid O₃,O₄-bis(propyloxy-O)borate

Downstream raw materials:

6-fluoro-8-methoxy-4-oxo-1-cyclopropyl-7-(2-(4-methylphenyl)sulfonyl-2,8-diazabicyclo[4.3.0]nonan-8-yl)-1,4-dihydroquinoline-3-carboxylic acid

Refernces

• 1、 -. "Synthetic method of moxifloxacin hydrochloride". Paragraph 0037-0057. . Retrieved 2020/07/13.
• 2、 -. "Preparation method of moxifloxacin hydrochloride (by machine translation)". Paragraph 0048-0055; 0066-0080. . Retrieved 2020/05/01.